Figure 6
MIRA-1 induced anti-myeloma activity in vivo. SCID mice (n=5 per group) were inoculated s.c. with 3 × 107 8226 cells in RPMI medium along with matrigel matrix. Tumour-bearing mice were randomly assigned into two cohorts receiving daily i.p. injection of MIRA-1 (10 mg kg−1) or with vehicle (PBS) alone for 15 days. (A) MIRA-1 treatment resulted in tumour growth inhibition (*P<0.05). (B) Prolonged survival was observed in the treatment group of mice (P=0.007). (C) No significant loss of body weight was observed. (D–F) MIRA-1 enhanced anti-tumour activity of dexamethasone in vivo. SCID mice were inoculated s.c. with 3 × 107 8226 cells in 100 μl RPMI medium together with matrigel matrix. Twenty tumour-bearing mice were randomly assigned to four groups and treated for 13 days with control (PBS), MIRA-1 (5 mg kg−1), dexamethasone (1 mg kg−1), or the combination once daily. At day 15, the treatment was discontinued and mice were monitored for tumour dynamics and body weight. (D) MIRA-1 and dexamethasone combination therapy triggered more potent inhibition of tumour growth in mice treated with MIRA-1 or dexamethasone alone or control (*P<0.05). (E) Combination therapy markedly prolonged survival compared with mice treated with control (P=0.003), MIRA-1 (P=0.005) or dexamethasone (P<0.045) alone. (F) Mice body weight was used to assess toxicity of the treatment. C = control; M = MIRA-1; D = dexamethasone; M+D = MIRA-1 + dexamethasone.
